Ilyang Pharmaceutical Co.,Ltd

KOSE:A007570 Stock Report

Market Cap: ₩201.8b

Ilyang PharmaceuticalLtd Past Earnings Performance

Past criteria checks 0/6

Ilyang PharmaceuticalLtd's earnings have been declining at an average annual rate of -12%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 3.1% per year.

Key information

-12.0%

Earnings growth rate

-12.0%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate3.1%
Return on equity0.8%
Net Margin-0.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) 28% Price Boost Is Out Of Tune With Revenues

Jan 06
Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) 28% Price Boost Is Out Of Tune With Revenues

Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Has A Meaningful Debt Burden

Jan 03
Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Has A Meaningful Debt Burden

Is Ilyang PharmaceuticalLtd (KRX:007570) A Risky Investment?

Apr 04
Is Ilyang PharmaceuticalLtd (KRX:007570) A Risky Investment?

Should You Be Adding Ilyang PharmaceuticalLtd (KRX:007570) To Your Watchlist Today?

Mar 14
Should You Be Adding Ilyang PharmaceuticalLtd (KRX:007570) To Your Watchlist Today?

Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely

Mar 14
Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely

Declining Stock and Decent Financials: Is The Market Wrong About Ilyang Pharmaceutical Co.,Ltd (KRX:007570)?

Feb 22
Declining Stock and Decent Financials: Is The Market Wrong About Ilyang Pharmaceutical Co.,Ltd (KRX:007570)?

Did Business Growth Power Ilyang PharmaceuticalLtd's (KRX:007570) Share Price Gain of 159%?

Feb 01
Did Business Growth Power Ilyang PharmaceuticalLtd's (KRX:007570) Share Price Gain of 159%?

Is Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) Shareholder Ownership Skewed Towards Insiders?

Jan 11
Is Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) Shareholder Ownership Skewed Towards Insiders?

Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Can Manage Its Debt Responsibly

Dec 24
Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

Dec 06
A Look At The Intrinsic Value Of Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Nov 18
Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Revenue & Expenses Breakdown

How Ilyang PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A007570 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24364,562-738141,40029,615
30 Jun 24366,053642140,39426,988
31 Mar 24368,707-3,358144,06427,959
31 Dec 23370,537-2,467142,88827,439
30 Sep 23367,4325,506143,93028,106
30 Jun 23380,6548,435145,82528,451
31 Mar 23378,43715,678143,61226,792
31 Dec 22383,81118,789146,35725,960
30 Sep 22389,45421,260146,51724,736
30 Jun 22376,53921,234143,24322,402
31 Mar 22374,95720,009140,80122,009
31 Dec 21371,34814,384140,49620,196
30 Sep 21351,56211,559135,12818,647
30 Jun 21353,2658,727130,36018,822
31 Mar 21353,7718,045130,57518,719
31 Dec 20343,32910,880124,82019,723
30 Sep 20336,95410,558123,82519,832
30 Jun 20324,1429,487125,15118,064
31 Mar 20319,2428,493123,36018,555
31 Dec 19324,5739,985127,63215,850
30 Sep 19323,111703127,26414,046
30 Jun 19311,322-5,138125,17815,086
31 Mar 19304,435-4,821123,56812,168
31 Dec 18300,036-4,893121,68212,844
30 Sep 18289,4606,970113,27115,045
30 Jun 18291,9748,474109,42913,408
31 Mar 18282,4629,139103,59512,889
31 Dec 17269,8116,26597,24412,387
30 Sep 17262,2144,47597,15311,098
30 Jun 17262,3236,10193,62810,686
31 Mar 17263,1595,20690,95710,937
31 Dec 16261,6155,84887,96910,806
31 Dec 15239,2634,40975,69414,390
30 Sep 15237,556-2,26678,1898,671
30 Jun 15226,844-4,44277,4758,850
31 Mar 15211,798-10,96276,0608,361
31 Dec 14195,872-9,19367,84210,669
30 Sep 14179,412-5,32059,08510,972
30 Jun 14158,829-53052,1478,832
31 Mar 14147,7323,96346,0877,424

Quality Earnings: A007570 is currently unprofitable.

Growing Profit Margin: A007570 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A007570 is unprofitable, and losses have increased over the past 5 years at a rate of 12% per year.

Accelerating Growth: Unable to compare A007570's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A007570 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.3%).

Return on Equity

High ROE: A007570 has a negative Return on Equity (0.8%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 08:01
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ilyang Pharmaceutical Co.,Ltd is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimCape Investment & Securities Co., Ltd.
Jae Hoon ShinLS Securities Co., Ltd.
Jaechul ParkMirae Asset Securities Co., Ltd. (Pre-Merger)